Page 43 - TD-1-2

Tumor Discovery Fact & challenges of immunotherapy in TNBC

tipiracil plus bevacizumab as a first-line treatment for elderly non-and triple-negative breast cancer. Clin Epigenetics,
patients with metastatic colorectal cancer (KSCC1602): 10: 88.
A multicenter phase II trial. Cancer Med., 10(2): 454–461.
82. Brown GC, 1994, Control analysis applied to the whole
76. Cortes J, Cescon DW, Rugo HS, et al., 2020, Pembrolizumab body: Control by body organs over plasma concentrations
plus chemotherapy versus placebo plus chemotherapy and organ fluxes of substances in the blood. Biochem J.,
for previously untreated locally recurrent inoperable or 297(Pt 1): 115–122.
metastatic triple-negative breast cancer (KEYNOTE-355): 83. Le DT, Durham JN, Smith KN, et al., 2017, Mismatch
A randomised, placebo-controlled, double-blind, phase 3 repair deficiency predicts response of solid tumors to PD-1
clinical trial. Lancet, 396(10265): 1817–1828.
blockade. Science, 357(6349): 409–413.
77. Garrido-Castro AC, Lin NU, Polyak K, 2019, Insights into 84. Patil NS, Nabet BY, Muller S, et al., 2022, Intratumoral
molecular classifications of triple-negative breast cancer: plasma cells predict outcomes to PD-L1 blockade in non-
Improving patient selection for treatment. Cancer Discov., small cell lung cancer. Cancer Cell, 40(3): 289–300.e4.
9(2): 176–198.
85. Fishman RF, Kuntz RE, Carrozza JP, Jr., et al., 1995, Acute
78. Turner NC, Reis-Filho JS, 2013, Tackling the diversity and long-term results of coronary stents and atherectomy in
of triple-negative breast cancer. Clin Cancer Res., 19(23): women and the elderly. Coron Artery Dis., 6(2): 159–168.
6380–6388.
86. Gianni L, Huang CS, Egle D, et al., 2022, Pathologic
79. Ntirenganya F, Twagirumukiza JD, Bucyibaruta G, et al., complete response (pCR) to neoadjuvant treatment with
Premenopausal breast cancer risk factors and associations or without atezolizumab in triple-negative, early high-risk
with molecular subtypes: A case-control study. Int J Breast and locally advanced breast cancer: NeoTRIP Michelangelo
Cancer, 2021: 5560559.
randomized study. Ann Oncol., 33(5): 534–543.
80. Elsamany S, Abdullah S, 2014, Triple-negative breast cancer: 87. Schmid P, Rugo HS, Adams S, et al., 2020, Atezolizumab
Future prospects in diagnosis and management. Med Oncol., plus nab-paclitaxel as first-line treatment for unresectable,
31(2): 834.
locally advanced or metastatic triple-negative breast
81. Bautista RR, Gomez AO, Miranda AH, et al., 2018, Long cancer (IMpassion130): Updated efficacy results from a
non-coding RNAs: Implications in targeted diagnoses, randomised, double-blind, placebo-controlled, phase 3 trial.
prognosis, and improved therapeutic strategies in human Lancet Oncol., 21(1): 44–59.

Volume 1 Issue 2 (2022) 11 https://doi.org/10.36922/td.v1i2.196